

Review

Not peer-reviewed version

Anti-Candida Phytochemicals and Isolated Compounds in Anacardiaceae Family—An Updated Review and In-Silico Analysis

[Aluisio Silva Oliveira](#) , Josivan Regis Farias , Danielle Cristine Gomes Franco , [Arthur Andre Castro da Costa](#) , Pamela Gomes Santos , [Mayara Cristina Pinto Silva](#) , Flavia Raquel Fernandes Nascimento , [Rosane Nassar Meireles Guerra](#) *

Posted Date: 16 April 2024

doi: 10.20944/preprints202404.1065.v1

Keywords: Anacardiaceae; gallic acid; ADMET; drug-likeness; Candida albicans; antifungal



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Anti-*Candida* Phytochemicals and Isolated Compounds in Anacardiaceae Family—An Updated Review and *In-Silico* Analysis

Oliveira A. S., Farias J.R., Franco D.C.G., Costa A.A.C, Santos P.G., Silva M.C.P., Nascimento F.R.F and Guerra R.N.M *

Laboratory of Immunophysiology and Programa de Pós-Graduação em Ciências da Saúde, Universidade Federal do Maranhão, Campus Bacanga, Av. dos Portugueses, 1966, 65080-805, São Luís, Maranhão, Brazil

* Correspondence: rosane.guerra@ufma.br; Tel.: +55-98-3272-8548

Abstract: Fungal infections caused by *Candida* spp. are responsible for high hospital morbidity and mortality rates. Therefore, there is a continuous search for new antifungal medicines, particularly ones with anti-*Candida* activity. This review analyzed articles published between 2002 and 2023 considering the anti-*Candida* activity of chemical compounds identified or isolated in plants of the Anacardiaceae family. In addition, the in-silico prediction of the isolated compounds described was performed. The analysis of 35 studies showed that extracts, essential oils, and compounds from the anti-*Candida* activity were frequently determined *in vitro* using the minimum inhibitory concentration (MIC). The most commonly tested species were *Candida albicans*, *C. tropicalis*, *C. parapsilosis*, *C. glabrata*, *C. krusei*, and *C. guilliermondii*, respectively. Essential oils were the most used form (37% of the studies). The isolated compounds with antifungal effects include cardanol, estragole, trans-anethole, β -caryophyllene, myrcene, catechin-3-o-rhamnoside, β -sitosterol-3-O-glucoside, 24Z-isomasticadienolic acid, oleanolic acid, and oleanolic aldehyde. The *in-silico* evaluation of those isolated compounds revealed the compounds' drug-likeness and possible antifungal activity. However, some of them showed high toxicity. In conclusion, compounds from the Anacardiaceae family show promise for developing new therapeutic antifungal drugs, especially in combination with conventional antifungals.

Keywords: Anacardiaceae; gallic acid; ADMET; drug-likeness; *Candida albicans*; antifungal

Significance statement

Fungal infections caused by *Candida* spp., mainly those caused by *Candida albicans*, are responsible for high morbidity and mortality. There is scientific evidence that extracts and isolated compounds from species of the Anacardiaceae family exert an antifungal effect. In addition, our in-silico analyses revealed the compounds' drug-likeness and possible antifungal activity. In conclusion, chemical compounds present in extracts from Anacardiaceae species may be used as targets to develop new antifungal drugs.

1. Introduction

Fungal infections have become more widespread and diverse worldwide. They account for the highest mortality rates and hospital-acquired infections [1,2]. According to estimates, *Candida* sp is responsible for 400,000 new cases of candidiasis every year. Mortality rates can range from 40% to 60% [3,4].

Candida spp. can colonize various human tissues and is part of the commensal microbiota, a barrier to the innate immune system. However, certain conditions can cause an imbalance in the microbiota, which can alter tissue integrity or lead to host immune response defects, resulting in the development of infections. Once established, these infections may cause disseminated candidiasis of deep organs, which has become a severe public health problem [5].

Candida albicans is the primary cause of candidiasis, even after the increase in infections caused by related species such as non-*albicans* [6]. The invasive capacity of *C. albicans* is related to several virulence factors, including the ability to switch from yeast to hyphal forms. Adhesion to synthetic materials or biological substrates favors the growth of more hyphae that are capable of producing extracellular polymers that provide a structural matrix and facilitate adhesion and biofilm formation. This contributes to the process of host tissue invasion [7–9].

Virulence factors associated with *Candida* species impair the treatment of candidiasis and favor resistance to commercial antifungals, including azoles such as fluconazole, echinocandins, and amphotericin B [10]. Despite their frequent application, some drugs are limited because of their high toxicity [10,11]. Efforts are being made to identify new therapeutic strategies, particularly natural compounds, to control fungal infections due to increased resistance to antifungal drugs in 2022 [11–13].

In finding treatments for fungal infections, the chemical composition of plant extracts can help identify substances with potential therapeutic effects against species of the *Candida* genus [14,15]. To discover and develop new drugs, various compounds are evaluated to identify their therapeutic, molecular, and pharmacokinetic properties [16]. In this regard, computational simulations using *in silico* molecular docking and molecular dynamics approaches can help with the rational design and screening of drugs [17].

This work aimed to study Anacardiaceae species' phytochemical composition and anti-candida properties, focusing on literature published from 2000 to 2023.

The present review aimed to find and compile data on the antifungal activity of chemical compounds identified in the Anacardiaceae family, considering the last ten years and evaluating *in silico* the prediction of the identified isolated compounds as a new drug candidate, considering their bioavailability and potential toxicity.

2. Material and Methods

2.1. Search Strategy

The analyses comprised the published studies in PubMed, Embase, Science Direct, and Scopus databases without language restrictions. The keywords used were Anacardiaceae and *Candida*, Anacardiaceae and anti-*Candida*, Anacardiaceae and antifungal activity, and Anacardiaceae and antifungal agent. The following inclusion criteria were applied to avoid bias: original articles published between March 2012 and December 2023; studies that performed chemical characterization or used compounds isolated from extracts of plants belonging to the family Anacardiaceae; and studies conducted *in silico*, *in vitro* or *in vivo* assays focusing on the anti-*Candida* activity.

For this review, we selected only studies that performed chemical characterization of the extracts or those using the isolated compounds. Studies performing only phytochemical screening were excluded since those methods have low sensibility and accuracy.

The initial search retrieved 455 articles. Some articles were indexed in two or more databases and removed to avoid duplicates. After an initial screening of titles and abstracts and subsequent full-text reading, 35 articles met the inclusion criteria. Figure 1 illustrates the process of article screening and selection for this review.




Figure 1. Flow chart of article screening and selection (2012-2023).

2.2. In Silico Pass Prediction

The structure of the isolated compounds identified in the Anacardiaceae family was retrieved from the PubChem database (<https://pubchem.ncbi.nlm.nih.gov/>) and included:

- 24Z-isomasticadienolic acid (PubChem CID: 15559978),
- cardanol (PubChem CID: 11266523),
- catechin-3-o-rhamnoside (PubChem CID: 21626704),
- estragole (PubChem CID 8815:), myrcene (PubChem CID: 31253),
- oleanolic acid (PubChem CID: 10494),
- Oleanolic aldehyde (PubChem CID: 10321055),
- trans-Anethole (PubChem CID: 637563),
- β -Caryophyllene (PubChem CID: 5281515) and
- β -sitosterol-3-O-glucoside (PubChem CID: 12309057).

The pass prediction of the antifungal potential of the selected compounds was reviewed with PASS online tools (<http://way2drug.com/passonline>). The Pa (Probable activity) and Pi (Probable inactivity) considering values ranged from 0.000 to 1.000 [18]. The compounds considered drugs with a potential to be biologically active must have Pa values higher than the Pi values. In comparison, $Pa < 0.7$ suggests high drug activity, $0.5 < Pa < 0.7$ shows moderate therapeutic potentials, and $Pa < 0.5$ shows poor pharmaceutical activity [19].

2.3. Pharmacokinetics and Toxicity Measurement

The SwissADME online method determined the compounds' pharmacokinetic properties, including Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADME/T) [16].

Compounds that obey Lipinski's rule are considered ideal drug Candidates (molecular weight not more than 500 g/mol; *Candida*-bond donors ≤ 5 ; *Candida*-bond acceptors ≤ 10 ; molar refractivity ranging from 40 to 130; and lipophilicity < 5 . [20].

In addition, the online tool GUSAR (<http://Candida.way2drug.com/gusar/acutoxpredict.html>) In silico prediction of LD50 values for oral administration in rats (LD50 values given in [mg/kg]: Class

I: fatal if swallowed ($LD50 \leq 5$); Class II: fatal by ingestion ($5 < LD50 \leq 50$); Class III: toxic by ingestion ($50 < LD50 \leq 300$); Class IV: harmful by ingestion ($300 < LD50 \leq 2000$); Class V: may be dangerous if ingested ($2000 < LD50 \leq 5000$); Class VI: non-toxic ($LD50 > 5000$) and OSIRIS Property Explorer (<https://Candida.organic-chemistry.org/prog/peo/>) was used to calculate the toxicological properties: mutagenic, tumorigenic, irritant and reproductive effective.

3. Results

3.1. The Anacardiaceae Family

The Anacardiaceae family comprises approximately 81 genera and 800 species worldwide in tropical and subtropical regions. It is economically significant because it provides edible fruits (mango, cashew, pistachio, and others), wood, and ornamental plants [21].

The family comprises woody plants with resiniferous ducts, glabrous or hairy branches, typically alternate leaves, usually simple, composite, or pinnate, mostly imparipinnate, with entire margin or serrated and without stipules. The flowers are bisexual, unisexual, or polygamous, actinomorphic, and are frequently arranged in terminal inflorescences, although they rarely may be solitary; they are usually pentamerous and commonly present with the nectariferous disc; 4-5-mer sepals, with 4-5-mer petals; the gynaecium is syncarpous, with 1–12 uninoculated carpels and super ovary. It has a white, greenish, or purplish color and free stamens. The fruits are usually of the drupe type. In Brazil, 55 species are distributed in 14 genera, and the most diverse are *Schinus* (11 species) and *Anacardium* (9 species) [22].

Some species are used in traditional medicine [23–25]. Furthermore, many studies investigated the antifungal activity of plant extracts of species such as *Rhus typhina* L. [26], *Anacardium occidentale* L. [27–29], and *Cottinus coggyria* Scop. [30,31] *Lannea kestingii* Engl and K.Krause [32,33]; *Mangifera indica* L. [34]; *Pistachia* sp. [35–40,42,43]; *Rhus* sp.[26,44]; *Schinopsis brasiliensis* Engl [46]; *Schinus* sp. [41,47–50] and *Spondias* sp. [51–53]. Several reports also related to the activity of isolated compounds [29], including cardanol, among others.

3.2. Anacardiaceae Species with Anti-Candida Activity

After analysis of the articles, 35 studies reporting anti-*Candida* activity of the family Anacardiaceae plant species were identified. Table 1 summarizes the plant species listed in alphabetical order and their respective extracts/fractions and plant parts used, the chemically characterized or isolated compounds, the *Candida* species or strain used in the studies, the type of assay, and methods used to assess anti-*Candida* activity. The Latin species names were validated at World Flora Online - WFO [54]. It is vital to clarify that each species' identity of the plant taxonomist(s) is reported only in Table 1.

The results identified 35 studies, 23 species belonging to 9 genera of Anacardiaceae with anti-*Candida* activity. This family has the most significant number of medicinal plants used in traditional medicine to treat infections [24,25].

The most prevalent genus was *Pistacia*, with nine studies [35–43], and *Schinus*, four studies [41; 47–50]. *Anacardium occidentale* was the species more investigated, with three studies [27–29], followed by *Cottinus coggyria* [30; 31] and *Lannea Kerstingii* [32,33], *Rhus typhina* [26;45], and *Spondias tuberosa* [51–53] with two studies. Other species also showed anti-*Candida* effects, including *Mangifera indica* [34], *Rhus coriaria* [44], *Schinopsis brasiliensis* [46], and *Spondias mombin* [51].

Essential oils were the most frequently used form, reported in 37.1% (n=12) of the studies. Extracts and essential oils were obtained from leaves (54.2%), bark (17.1%), seeds (8.6%), fruits (8.6%), hulls (8.6%), flowers (5.7%), roots (2.9%), and nutshells (2.9%).

C. albicans was the most frequently tested strain, corresponding to 74.3% of the studies, followed by *C. tropicalis* (22.9%), *C. parapsilosis* (17.1%), *C. glabrata* (11.4%), *C. krusei* (11.4%), and *C. guilliermondii* (2.9%).

The anti-*Candida* activity of extracts and compounds was frequently determined by halo inhibition on microbiological media (21%), minimum inhibitory concentration (MIC – 89%), and

minimum fungicidal concentration (MFC – 21%). Only two studies evaluated the effect on biofilm formation, one study on exoenzymes (proteinase and phospholipase), and one study on the growth curve. It is essential to highlight that only one study conducted *in vivo* tests in rats to evaluate the anti-*Candida* activity in a model of vulvovaginal candidiasis, and the remaining studies performed *in vitro* assays.

Table 1. Extracts and active compounds of plants of the family Anacardiaceae with anti-*Candida* activity (2012 to 2023).¹.

Plant Species	Type of extract or fraction (Plant part)	Compounds identified and/or isolated	<i>Candida</i> species tested	Type of assay (methods)*	Reference
<i>Anacardium occidentale</i> L.	Ethanollic (Flowers, leaves, stem bark)	Phosphoric acid, dodecanoic acid, ethylgallic acid, sorbitol, glucose, gallic acid, hexadecanoic acid, octadecanoic acid and 1,2- benzenedicarboxylic acid	<i>C. albicans</i> <i>C. tropicalis</i>	<i>In vitro</i> (Halo diffusion, MIC, MFC)	[27]
	Ethanollic (bark)	Gallic acid, luteolin, epicatechin gallate and flavone	<i>C. albicans</i> , <i>C. krusei</i> <i>C. tropicalis</i>	<i>In vitro</i> (MIC)	[28]
	(NI)* Cashew nutshell	Cardanol (Isolated compound)	<i>C. albicans</i>	<i>In vitro</i> (MIC)	[29]
<i>Cotinus coggyria</i> Scop	Essential oil (leaves)	α -pinene β -pinene limonene α -terpinolene β -terpinene β -myrcene β -caryophyllene	<i>C. albicans</i> <i>C. parapsilosis</i>	<i>In vitro</i> (Halo diffusion)	[30]
	Ethyl alcohol (Leaves and flowers)	Rutin ferulic acid quercetin gallic acid kaempferol sulphurein, 3,3',4',5,6,7 - hexahydroxyflavone, 7-O- β -D glucopyranoside	<i>C. albicans</i>	<i>In vitro</i> (Halo diffusion)	[31]
<i>Lannea kerstingii</i> Engl. and K. Krause.	Ethyl acetate (Stem bark)	β-sitosterol-3-O-glucoside (Isolated compound)	<i>C. albicans</i> , <i>C. tropicalis</i> <i>C. krusei</i>	<i>In vitro</i> (Halo diffusion, MIC, MFC)	[32]
	Ethyl acetate (Stem bark)	catechin-3-o-rhamnoside (Isolated compound)	<i>C. albicans</i> <i>C. tropicalis</i>	<i>In vitro</i> (MIC, MFC)	[33]

<i>Mangifera indica</i> L.	NI (peel and seed)	Proanthocyanidins gallates gallotannins	<i>C. parapsilosis</i> <i>C. glabrata</i>	<i>In vitro</i> (Halo diffusion MIC)	[34]
	Essential oil (Leaves, fruits)	α -pyrene, terpinen-4-ol acid	<i>C. albicans</i>	<i>In vitro</i> (MIC)	[35]
<i>Pistacia atlantica</i> Desf.	Methanolic (leaves)	gallic acid, ellagic acid, 3,3'-dimethoxyellagic acid, gallotannins, 2,3-di-O-galloyl-(α/β)-4 C1 - glucopyranose, nilocitin, 1,3-di- O-galloyl- β -D-4, C1-glucopyranose and 1,2,3,4,6- penta-O-galloyl- β -D-4	<i>C. albicans</i>	<i>In vitro</i> (Halo diffusion)	[36]
	Essential oil (hulls)	α -Pinene, β -citral, carvone hydrate, myristic acid, p- acetyltoluene, pinocarveol and palustrol	<i>C. albicans</i>	<i>In vitro</i> (Halo diffusion, MIC)	[37]
<i>Pistacia atlantica</i> subsp.	Mastic gum	24Z-isomasticadienolic acid, oleanolic acid, oleanonic aldehyde (Isolated compounds)	<i>C. albicans</i>	<i>In vitro</i> (MIC)	[38]
	Oils (seeds)	Linoleic acid, oleic acid, fatty acid, β -sitosterol, protocatechuic acid, p-coumaric, t-cinnamic	<i>C. albicans</i>	<i>In vitro</i> (halo diffusion)	[39]
<i>Pistacia lentiscus</i> L.	Essential oil (leaves)	α -pinene, terpinen-4-ol and other 62 compounds	<i>C. albicans</i> <i>C. glabrata</i>	<i>In vitro</i> (MIC)	[40]
<i>Pistacia terebinthus</i> L.	Essential oils (leaves)	Monoterpene hydrocarbons, α -pinene camphene, β -pinene terpinolene, β -phellandrene	<i>C. albicans</i>	<i>In vitro</i> (MIC)	[41]
<i>Pistacia vera</i> L.	Essential oil (hulls)	α -Pinene α -terpineol, camphene D- limonene and 3-carene	<i>C. albicans</i> , <i>C. parapsilosis</i>	<i>In vitro</i>	[42]

			<i>C. glabrata</i>	(MIC, MFC, growth curve)	
		Cyanidin-3- <i>O</i> -galactoside, gallic acid, catechin, eriodictyol-7- <i>O</i> -glucoside	<i>C. albicans</i> <i>C. glabrata</i> <i>C. parapsilosis</i> <i>C. auris</i>	<i>In vitro</i> (MIC)	[43]
<i>Rhus coriaria</i> L.	Essential oil (seeds)	Linoleic acid, oleic acid, palmitic acid	<i>C. albicans</i>	<i>In vitro</i> (Halo diffusion, MIC)	[44]
	Hydroalcoholic extract, essential oil (Branches, leaves, and fruits)	Gallic acid, 1-cyclohexane-3,4,5-hydroxy-carboxylic acid, malic acid, d-cadinene, β -pinene, phenylacetaldehyde	<i>C. albicans</i>	<i>In vitro</i> (Halo diffusion, MIC)	[26]
<i>Rhus typhina</i> L	Ethanollic (leaves and berries)	Gallic acid, chlorogenic acid, gentisic acid, sinapic acid, caffeic acid, ethyl gallate	<i>C. albicans</i>	<i>In vitro</i> (MIC)	[45]
<i>Schinopsis brasiliensis</i> Engl.	Essential oil (leaves)	Estragole <i>trans</i>-anethole, β-caryophyllene myrcene (Isolated compounds)	<i>C. parapsilosis</i>	<i>In vitro</i> (MIC)	[46]
<i>Schinus lentiscifolius</i> Marchand.	Aqueous, n-hexane, ethyl acetate and n-butanol fractions (leaves)	Nonadecanol, moronic acid, gallic acid methyl ester, gallic acid, quercetin, quercitrin	<i>C. albicans,</i> <i>C. tropicalis</i>	<i>In vitro</i> (MIC)	[47]

<i>Schinus molle</i> L.	Petroleum ether, diethyl ether, acetone, aqueous (leaves)	Sesquiterpenes, sesquiterpenoids and other terpenes	<i>C. albicans</i>	<i>In vitro</i> (Halo diffusion; MIC)	[48]
<i>Schinus polygamus</i> Cav.	Essential oil (Bark and leaves)	<i>dl</i> -limonene myrtenal caryophyllene oxide (bark). E-caryophyllene <i>dl</i> -limonene β -pinene (leaves)	<i>C. albicans</i>	<i>In vitro</i> (MIC)	[49]
	Essential oil (Leaves and fruits)	A-phellandrene, β -phellandrene, α -pinene, and germacrene D	<i>C. albicans</i> , <i>C. tropicalis</i> , <i>C. krusei</i> , <i>C. guillermondii</i> <i>C. parapsilosis</i>	<i>In vitro</i> (MIC)	[41]
<i>Schinus weinmannifolius</i> Engl	Essential oil (leaves)	Bicyclogermacrene, limonene	<i>C. albicans</i>	<i>In vitro</i> (MIC)	[50]
<i>Spondias mombin</i> L.	Aqueous (leaves)	Quercetin caffeic acid catechin	<i>C. albicans</i>	<i>In vitro</i> (MIC; MFC)	[51]
	hydroethanolic (bark)	kaempferol phenols flavonoids	<i>C. tropicalis</i>		
<i>Spondias tuberosa</i> Arruda.	Hexane (leaves)	Flavonoids, hydrolysable tannins, saponins, terpenes; gallic acid, saturated and unsaturated fatty acids	<i>C. albicans</i> , <i>C. parapsilosis</i> , <i>C. glabrata</i> , <i>C. krusei</i>	<i>In vitro</i> (MIC; MFC)	[52]
	Hydroalcoholic (Leaves and roots)	Alkaloids, steroids, phenols, flavonoids, triterpenoids, xanthones; dehydroascorbic acid, quinic acid, and others	<i>C. albicans</i> , <i>C. tropicalis</i>	<i>In vitro</i> (MIC, morphological transition)	[53]

(*) NI – not informed in the article; MIC – Minimum Inhibitory Concentration; MFC – Minimum Fungicidal Concentration.

3.3. Isolated Compounds with Anti-CANDIDA activity

The anti-*Candida* activity of the following ten isolated compounds was assessed *in vitro*: cardanol [29], β -sitosterol-3-O-glucoside [32], catechin-3-o-rhamnoside [33], 24Z-isomasticadienolic acid, Oleanolic acid, and Oleanolic aldehyde [38], estragole, myrcene, Trans-anethole, β -caryophyllene [46]. There was also a wide range of chemically characterized compounds among species whose activity was not directly assessed. The most common substance identified was gallic acid [26–28,31,36,43,45,47,52], α -pinene [30,31,37,40–42] and limonene [30,42,49,50]. **Figure 2** shows the chemical structure of the ten isolated compounds.




Figure 2. Chemical structure of the identified and isolated compounds in extracts from plants of the family Anacardiaceae with antifungal activity against *Candida* ssp.

3.3.1. In Silico Prediction of Anti-Candida Activity of Isolated Compounds

The *in-silico* evaluation of isolated compounds showed they all have a higher Potential activity (Pa) than potential inactivity (Pi). Catechin-3-o-rhamnoside (Pa=0.740) and β -sitosterol-3-O-glucoside (Pa=0.722) showed the highest molecular potency, followed by the 24Z-isomasticadienolic acid (Pa=0.687). The other compounds exhibited Pa between 0.590 and 0.425 (**Table 2**).

Table 2. PASS prediction of isolated compounds identified in the Anacardiaceae family for antifungal activity.

Isolated compounds	Potential activity (Pa)	Potential inactivity (Pi)
24Z-isomasticadienolic acid	0.687	0,010
Cardanol	0.543	0.024
Catechin-3-o-rhamnoside	0.740	0,008
Estragole	0.425	0.045
Myrcene	0.584	0.020

Oleanolic acid	0.575	0.021
Oleanolic aldehyde	0.590	0.019
<i>Trans</i> -Anethole	0.444	0.040
β -Caryophyllene	0.582	0.020
β -sitosterol-3-O-glucoside	0.722	0.009

Pa (Pa >0.7 – high drug activity; 0.5 < Pa < 0.7 – moderate drug activity; and Pa < 0.5 – poor drug activity).

3.3.2. Toxicity and Oral Bioavailability of Isolated Compounds

The results showed that all the compounds met Lipinski's rules and showed oral bioavailability. Concerning probable toxicological effects, the oleanolic acid showed reproductive toxicity, trans-anethole may have mutagenic, tumorigenic, and irritant effects, and myrcene may act as a tumorigenic, irritant, and reproductive toxic product. All other compounds did not show mutagenic, tumorigenic, irritant, or reproductive toxicity (Table 3).

Table 3. Potential oral bioavailability of isolated compounds with anti-*Candida* activity.

Compounds	MW ^a (g/mol)	HBD ^b	HBA ^c	LogP ^d (o/w)	MR ^e	GA ^f
24Z-isomasticadienolic acid	454.6	1	3	4.09	137.8	Low
Cardanol	298.4	1	1	4.61	99.3	Low
Catechin-3-o-rhamnoside	436.5	7	10	1.58	105.5	Low
Estragole	148.2	0	1	2.47	47.0	High
Myrcene	136.2	0	0	2.89	48.7	Low
Oleanolic acid	456.7	2	3	3.89	136.6	Low
Oleanolic aldehyde	440.7	1	2	4.33	135.0	Low
<i>Trans</i>-Anethole	145.2	0	1	2.55	47.8	High
β -Caryophyllene	204.3	0	0	3.29	68.7	Low
β -sitosterol-3-O-glucoside	576.8	4	6	4.98	165.6	Low

a: MW = Molecular Weight (acceptance range <500); b: HBD = hydrogen-bond donor (acceptance range ≤ 5); c: HBA = hydrogen-bond acceptor (acceptance range ≤ 10); d: LogP = lipophilicity (acceptance range <5); e: MF = Molar Refractivity (acceptance range - 40-130); f: GA = Gastrointestinal Absorption.

The prediction of oral toxicity showed that the oleanolic aldehyde might be toxic by ingestion (Class III estimative). The oleanolic acid, β -sitosterol-3-O-glucoside, estragole, and 24Z-isomasticadienolic acid were considered Class IV compounds, with a probable harmful if swallowed. In addition, cardanol, catechin-3-o-rhamnoside, trans-anethole, β -caryophyllene and myrcene, Class V, may be dangerous if ingested (Table 4).

Table 4. Toxicity of isolated compounds with antifungal potential identified in Anacardiaceae family.

Compounds	MP ^a	TP ^b	IR ^c	RE ^d	Oral toxicity (LD50 ^e mg/Kg)
24Z-isomasticadienolic acid	No	No	No	No	1688
Cardanol	No	No	No	No	3737
Catechin-3-o-rhamnoside	No	No	No	No	2452
Estragole	No	No	No	No	1290
Myrcene	No	Yes	Yes	Yes	2561

Oleanolic acid	No	No	No	Yes	369.6
Oleanolic aldehyde	No	No	No	No	260.2
Trans-Anethole	Yes	Yes	Yes	No	3243
β -Caryophyllene	No	No	No	No	2331
β -sitosterol-3-O-glucoside	No	No	No	No	1279

a: MP - Mutagenic Potential.; b: TM - Tumorigenic Potential.; c: IR- Irritant Response.; d: Reproductive effects; and e: LD 50 = Lethal Dose 50.

4. Discussion

The high frequency of *C. albicans* as the target found in this review may be related to the high frequency with which this fungus is detected in infections, especially in vulvovaginitis [55]. Over the years, in parallel to the advance of medical procedures, the incidence of bloodstream *C. albicans* is still the most frequent yeast isolated from patient biological samples with severe and fatal clinical conditions in humans [6,55,56], mainly in patients with COVID-19 admitted to intensive care units [57]. The pathogenicity of *C. albicans* and other *Candida* species is related to several escape mechanisms, such as adhesion, biofilm formation, secretion of hydrolytic exoenzymes and increased resistance to available medicines [58]. Despite this knowledge, only a few studies have been conducted against the virulence factors.

In the present study, *A. occidentale* was the most prevalent species investigated for anti-*Candida* activity, considering the extracts obtained from the leaves, flowers, and stems [27,28] or compounds isolated from the cashew nutshell [29], which was effective against *C. albicans*. This species' antimicrobial activity is extensively studied, notably its antibacterial properties [27]. However, the anti-*Candida* activity related to identified or isolated substances is still scarce. Cardanol was found among the isolated compounds with anti-*Candida* activity [29]. The antifungal effect of cardanol is associated with its ability to bind to chitin on the cell wall [29]. At the same time, the phenolic acids may act against *Candida sp.* through different biological pathways and cellular targets compared to the existing antifungal agents [59]. Interestingly, anacardic acid, considered a marker of the *Anacardium* genus, was not included as an antifungal agent nor identified in the studies evaluated in this review.

Several studies have shown the genus *Pistacia* anti-*Candida* activity. These species are essential in many communities' nutrition and agricultural economy. This genus has been extensively studied in botany, ethnobotany, phytochemistry, and pharmacological activity [60,61]. Three studies evaluated *Pistacia atlantica* anti-*Candida albicans* activity using the oil extracted from the hulls [37], mastic gum [38] and the seeds oil. The anti-*C. albicans* activity related to three isolated compounds, 24Z-isomasticadienoic acid, oleanonic acid, and oleanonic aldehyde, was detected by Karyginanni et al. [38] evaluating the antifungal effect *in vitro*.

Pistacia lentiscus exerts antifungal activity against *C. albicans* and *C. glabrata*. This property has been attributed to compounds like α -pinene and terpinene-4-ol in the essential oils extracted from the leaves [40]. Similarly, the essential oil extracted from the leaves of *Pistacia terebinthus* also showed anti-*C. albicans* activity associated with the presence of α -pinene [41].

The antifungal effect of the essential oil of *Pistacia vera* was associated with similar compounds identified in the essential oil of *P. atlantica* [42]. The antifungal activity of *P. vera* was associated with gallic acid and catechin identified in the leaves' essential oil [13]. In addition, the essential oil was also effective against *C. glabrata*, *C. parapsilosis* and *C. aurisi* [44].

Studies on the susceptibility of *Candida spp.* have mostly followed the Clinical and Laboratory Standards Institute's (CLSI [62] standard M27-A3 recommendations. Therefore, the most used methods for evaluating extracts and compounds are determining the minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) using broth dilution [62]. However, the standard that establishes these methods was developed to test antimicrobials with already-known parameters, leading us to conclude that there is an urgent need to establish procedures to evaluate plant extracts' antifungal and antimicrobial activity.

Identifying bioactive compounds in plant extracts for experimental purposes comprises a series of essential steps, including determining the quality and quantity of the compounds considering the choice of solvent, extraction method, phytochemical screening procedure, fractionation method, and identification technique [15,16,63].

Our results showed that chemical analysis frequently involved the extraction of essential oils and the investigation of their antifungal activity of essential oils and their components [30,31,33–35,37,41,42,44,46,50], and isolated compounds as estragole, trans-anethole, b-caryophyllene, and myrcene [46]. In a study by Donati et al. [46], these compounds were isolated from the essential oil of *Schniopsis brasiliensis* and showed fungicidal activity against *C. parapsilosis*.

According to Donadu et al. [64], *Ruta graveolens* essential oil, which contains as the main component 2-undecanone, showed antifungal activity against fluconazole-resistant *C. tropicalis* and was also able to remove *C. albicans* biofilms partially. The time-kill kinetics assay revealed a fungicidal effect against *C. tropicalis* and a fungistatic activity against *C. albicans*. They also found a synergistic effect for the essential oil when combined with amphotericin B, a commercial antifungal. These findings suggest that natural products and isolated substances could be used as adjuvants to commercial antifungal treatments.

The compounds α -pyrene, limonene, and gallic acid were the most frequently identified in the Anacardiaceae family. α -Pyrene and limonene are determined mainly in essential oils and are reported as responsible for the anti-*Candida* activity. Gallic acid and its derivatives are secondary polyphenolic metabolites frequently detected in several Anacardiaceae species. Their salts and esters, called gallates, are widely distributed in plants and found in *A. occidentale* bark [27,28], *Mangifera indica* peel and seeds [34], and *Rhus typhina* leaves and berries [45], for example. There is evidence that liposomes containing quercetin and gallic can inhibit the fungus growth. In addition, the gallic acid anti-*C. albicans*' activity improved survival in a murine model of systemic infection and showed antioxidant and anti-inflammatory properties [65]. Other studies confirm gallic acid's promising role as an antifungal agent [66].

β -Sitosterol-3-O-glucoside and catechin-3-O-rhamnoside, compounds isolated from the stem bark of *Lannea kerstingii*, exhibited activity against *C. albicans* and *C. tropicalis* [33]. β -sitosterol-3-O-glucoside showed antiapoptotic activity [67], and catechin-3-O-rhamnoside has antioxidant [68], anti-inflammatory and anticancer properties [69] in studies with other plant families. However, we found no other reports of anti-*Candida* activity among the Anacardiaceae species. According to our *in-silico* results, β -sitosterol-3-O-glucoside showed high antifungal potential activity and low toxicity. However, the use of this substance as a new drug seems challenging due to its low gastrointestinal absorption.

Estragole, trans-anethole, and myrcene, compounds isolated from essential oils extracted from the leaves of *Schinopsis brasiliensis*, exerted activity against *C. parapsilosis* [46]. Synergistic activity between this substance and ketoconazole has been reported against *C. tropicalis*. In this case, the time-kill curves showed significant synergism between the medicine and the isolated compound. In contrast, the combination with amphotericin B had an antagonistic effect and was ineffective, and the fungus remained alive [70].

In a checkerboard study, Dąbrowska et al. [71] studied the anti-*Candida* effect of isolated compounds. They showed that the combination of trans-anethole and miconazole affected the cell composition of *C. albicans* and resulted in fungus death due to increased membrane permeability. Our results *in silico* showed high intestinal absorption, low toxicity to estragole, and poor potential activity. In contrast, the prediction for trans-anethole indicates that this substance is not a good choice as a target for a new antifungal agent since it presented poor potential activity and high toxicity, besides the high gastrointestinal absorption.

Myrcene is one of the main compounds found in essential oils of plant species such as *Cotinus coggyria*, exhibiting activity against *C. albicans* and *C. parapsilosis* [30]. However, the *in-silico* prediction showed that myrcene has a moderate potential activity but seems highly toxic, due to its tumorigenic, irritant, and harmful reproductive effects.

Molecular docking studies have been widely used to predict ligand-target interactions and obtain better insights into the biological activity of natural products. We utilized the structure-based biological activity prediction program Prediction of Activity Spectra for Substances (PASS) to predict the pharmacological profile of the identified compounds.

All compounds isolated and cited in this review were further characterized using the online-based prediction program ADME analysis to explore their drug-likeness, pharmacokinetics, and physiochemical characteristics. All compounds exhibited orally active drug-likeness properties, according to Lipinski's rule [20], since they have good bioavailability [16]. However, this analysis was not able to identify the particular pharmacological effect. After OSIRIS evaluation, it was possible to observe that some isolated compounds seem to be not safe as therapeutic drugs for humans, especially compounds such as myrcene (tumorigenic, irritating, and with harmful effects on the reproductive system), oleanolic acid (effects on the reproductive system) and trans-anethole (mutagenic, tumorigenic, and irritating).

5. Conclusions

Considering the drug-likeness characteristic, the Anacardiaceae family plant species and their isolated compounds may be used for bioprospecting new therapeutic agents with anti-*Candida* activity. Some isolated substances could be used as an adjuvant to commercial antifungal treatments. However, despite advances in improving the current antifungal arsenal and identifying new therapeutic targets, research has been limited to the early stages of infection, without focusing on the fungus virulence factors or the toxicity of the isolated compounds for the mammalian organism. Other questions are related to the urgent need to establish procedures to evaluate plant extracts' antifungal and antimicrobial activity. This is a crucial step in the fight against fungal infections and should be prioritized to identify the Anacardiaceae family's new plant-derived antifungals and compounds.

Taken together, the results of this review indicate that there is still a long road to identify, characterize, isolate, and test the compounds present in plants of the Anacardiaceae family as a sustainable option for new therapeutic agents to prevent or reduce the spread of fungal infections, especially those caused by *Candida* spp, the most common species in hospitals.

Declaration of Conflict of Interest: All authors declare that there is no conflict of interest.

Abbreviations

NI – not informed in the article; MIC: Minimum Inhibitory Concentration; MFC: Minimum Fungicidal Concentration; MW: Molecular Weight; HBD: hydrogen-bond donor; HBA: hydrogen-bond acceptor; LogP: values of lipophilicity; MF: Molar Refractivity; GA: Gastrointestinal Absorption; MP: Mutagenic Potential; TM: Tumorigenic Potential; IR: Irritant Response; LD 50: Lethal Dose 50.

References

1. Bitar I, Khalaf RA, Harastani C, Tokajian S. Identification, typing, antifungal resistance profile, and biofilm formation of *Candida albicans* isolates from Lebanese hospital patients. *Biomed Res Int* **2014**, 1: 1-10
2. Kainz K, Bauer MA, Madeo F, Carmona-Gutierrez D. Fungal infections in humans: the silent crisis. *Microb Cell* **2020**, 7: 143-145. doi: 10.15698/mic2020.06.718.
3. Pal M. Morbidity and mortality due to fungal infections. *J App Micro Biol* **2018**, 1: 1-10
4. Tsay SV, Mu C, Williams S, Epton E, Nadle J, Bamberg CM, Barter DM, Johnston CL, Farley MM, Harb S. Burden of candidemia in the United States, 2017. *Clin Infect Dis* **2020**, 71: e449–e453.
5. Rai LS, Wijlick LV, Bougnoux ME, Bachellier-Bassi S, d'Enfert C. Regulators of commensal and pathogenic lifestyles of an opportunistic fungus-*Candida albicans*. *Yeast* **2021**, 38:243-250. Doi: 10.1002/yea.3550.
6. Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. *Nat Rev Dis* **2018**, 4: 1–20.
7. Banu SF, Rubini D, Shanmugavelan P, Murugan R, Gowrishankar S, Pandian SK, Nithyanand P. Effects of patchouli and cinnamon essential oils on biofilm and hyphae formation by *Candida* species. *J Mycol Med* **2018**, 28: 332–339.

8. Talapko J, Juzbašić M, Matijević T, Pustijanac E, Bekić S, Kotris I, Škrlec I. *Candida albicans*-The virulence factors and clinical manifestations of infection. *J Fungi (Basel)* **2021**, 7: 79. doi: 10.3390/jof7020079.
9. Lopes JP, Lionakis MS. Pathogenesis, and virulence of *Candida albicans*. *Virulence* **2022**,13: 89-121. doi: 10.1080/21505594.2021.2019950.
10. Cui X, Wang L, Lü Y, Yue C. Development and research progress of anti-drug resistant fungal drugs. *J Infect Public Health* **2022**,15: 986-1000. doi: 10.1016/j.jiph.2022.08.004.
11. Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. *Drugs* **2013**,73: 919–934.
12. Colombo AL, Júnior JN, Guinea J. Emerging multidrug-resistant *Candida* species. *Curr Opin Infect Dis* **2017**, 30: 528–538.
13. Gonzalez-Lara MF, Ostrosky-Zeichner L. Invasive candidiasis. *Semin Respir Crit Care Med* **2020**, 41: 3-12. doi: 10.1055/s-0040-1701215.
14. Pedroso RS, Balbino BL, Andrade G, Dias MCPS, Alvarenga TA, Pedroso RCN, Pimenta LP, Lucarini R, Pauletti PM, Januário A. *In vitro* and *in vivo* anti-*Candida spp.* activity of plant-derived products. *Plants* **2019**, 8: 494- 521.
15. Zou X, Zeng M, Huang F, Qin G, Song Z, Liu F. The potential role of plant secondary metabolites on antifungal and immunomodulatory effect. *Appl Microbiol Biotechnol* **2023**, 4471-4492. Doi 10.1007/s00253-023-12601-5.
16. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness, and medicinal chemistry friendliness of small molecules. *Sci Rep* **2017**, 7: 1–13.
17. Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. *Int J Mol Sci* **2019**, 20, 4331.
18. Mojumdar M, Kabir MSC, Hasan MS, Ahmed T, Rahman MR, Akter C, Rahman MM. Molecular docking and pass prediction for the analgesic activity of some isolated compounds from *Acalypha idica* L. and ADME/T property analysis of the compounds. *World J Pharm Res* **2016**, 5: 1761–1770.
19. Goel RK, Singh D, Lagunin A, Poroikov V. PASS-assisted exploration of new therapeutic potential of natural products. *Med Chem Res* **2011**, 20: 1509–1514.
20. Lipinski CA, Lombardo F, Dominy BC, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev* **1997**, 23: 3–25.
21. Pell SK, Mitchell JD, Miller AJ, Lobo TA. Anacardiaceae. In: Kubitzki, K., ed. The families and genera of vascular plants. Flower. *Plants, Eudicots-Sapindales, Cucurbitales, Myrtaceae* 2011, 10: 7–50.
22. J Hall CF, Bragança AS. Flora das cangas da Serra dos Carajás, Pará, Brasil: Anacardiaceae. *Rodriguesia* **2017**, 68, n.3: 911-916. <https://doi.org/10.1590/2175-78602017683222017>.
23. Masevhe NA, McGaw LJ, Eloff JN. The traditional use of plants to manage candidiasis and related infections in Venda, South Africa. *J Ethnopharmacol* **2015**, 168: 364–372.
24. Novaryati S, Indah I. The medicinal plants used in Anjir Pulang Pisau, Central Kalimantan-Indonesia. *Pharmacogn J* **2019**, 11: 12-32
25. Baldé MA, Tuenter E, Traoré MS, Matheussen A, Cos P, Maes L, Camara A, Haba NL, Gomou K, Diallo MST. Antimicrobial investigation of ethnobotanically selected guinean plant species. *J Ethnopharmacol* **2020**, 263: 113-232.
26. Arlandini E, Gelmini F, Testa C, Angioletti S, Beretta, G (2021) GC-MS analysis and biological activity of hydroalcoholic extracts and essential oils of *Rhus typhina* L. wood (Anacardiaceae) in comparison with leaves and fruits. *Nat Prod Res* **2021**, 35: 4764–4768.
27. Silva RA, Liberio SA, Amaral FMM, Nascimento FRF, Torres LMB, Monteiro-Neto, V, Guerra RNM. Antimicrobial and antioxidant activity of *Anacardium occidentale* L. flowers in comparison to bark and leaves extracts. *J Biosci Med* **2016**, 4: 87- 99.
28. Costa AR, Almeida-Bezerra JC, Silva TG, Pereira PS, Oliveira Borba EF, Braga AL, Fonseca VJA, Menezes SA, Silva FSC, Sousa Fernandes PA. Phytochemical profile and anti-*Candida* and cytotoxic potential of *Anacardium occidentale* L. (cashew tree). *Biocatalysis Agric Biotechnol* **2021**, 37: 102-192.
29. Mahata D, Mandal SM, Bharti R, Gupta VK, Mandal M, Nag A, Nando GB. Self-assembled cardanol azo derivatives as antifungal agent with chitin-binding ability. *Int J Biol Macromol* **2014**, 69: 5–11.
30. Ulukanli Z, Karabörklü S, Bozok F, Çenet M, Öztürk B, Balcilar M. Antimicrobial, insecticidal and phytotoxic activities of *Cotinus coggyria* Scop. essential oil (Anacardiaceae). *Nat Prod Res.* **2014**, 28 (23): 2150-2157. doi: 10.1080/14786419.2014.928879.
31. Sukhikh S, Noskova S, Pungin A, Ivanova S, Skrypnik L, Chupakhin E, Babich O. Study of the Biologically Active Properties of Medicinal Plant *Cotinus coggyria*. *Plants (Basel).* **2021**,10(6):1224. doi: 10.3390/plants10061224.
32. Njinga NS, Sule MI, Pateh UU, Hassan CS, Abdullahi ST, Ache RN. Isolation and antimicrobial activity of β -sitosterol-3-O-glucoside from *Lannea kerstingii* Engl. & K. Krause (Anacardiaceae). *J Heal Allied Sci* **2016**, 6: 4–8.

33. Stanislaus NN, Ibrahim SM, Usman PU, Sa'adiya CC, Garba MM, Toyin AS, Moji B-OT, Ndifor AR, Osas EG, Oyetunji SA. Antimicrobial and antioxidant activity of catechin-3-o-rhamnoside isolated from the stem bark of *Lannea kerstingii* Engl. and K. Krause (Anacardiaceae). *Pakistan J Pharm Sci* **2021**, 34: 1-10.
34. Dorta E, González M, Lobo MG, Laich F (2016) Antifungal activity of mango peel and seed extracts against clinically pathogenic and food spoilage yeasts. *Nat Prod Res* 30: 2598–2604. <https://doi.org/10.1080/14786419.2015.11.15-25>.
35. Benabdallah FZ, Kouamé RO, El Bentchikou M, Zellagui A, Gherraf N (2017) Études ethnobotanique, phytochimique et valorisation de l'activité antimicrobienne des feuilles et de l'oléorésine du pistachier de l'atlas (*Pistacia atlantica* Desf.). *Phytothérapie* 15: 222–229.
36. Othman S, El-Hashash M, Hussein S, El-Mesallamy A, Rizk S, Elabbar FA (2019) Phenolic content as antioxidant and antimicrobial activities of *Pistacia atlantica* Desf. (Anacardiaceae) extract from Libya. *Egypt. J Chem* 62: 21–28.
37. Hasheminya S-M, Dehghannya J (2020) Composition, phenolic content, antioxidant, and antimicrobial activity of *Pistacia atlantica* subsp. *Kurdica* Hulls' essential oil. *Food Biosci* 34: 100-510.
38. Karygianni L, Cecere M, Argyropoulou A, Hellwig E, Skaltsounis AL, Wittmer A, Tchorz JP, Al-Ahmad A (2019) Compounds from *Olea europaea* and *Pistacia lentiscus* inhibit oral microbial growth. *BMC Complement Altern Med* 19: 1–10.
39. Brahmi F, Haddad S, Bouamara K, Yalaoui-Guellal D, Prost-Camus E, Barros J-PP, Prost M, Atanasov AG, Madani K, Boulekbache-Makhlouf L (2020) Comparison of chemical composition and biological activities of Algerian seed oils of *Pistacia lentiscus* L., *Opuntia ficus indica* (L.) Mill. and *Argania spinosa* L. Skeels. *Ind Crops Prod*. 151: 112-456.
40. Milia E, Usai M, Szotáková B, Elstnerová M, Králová V, D'hallewin G, Spissu C, Barberis A, Marchetti M, Bortone A, Campanella V, Mastandrea G, Langhansová L, Eick S (2020) The pharmaceutical ability of *Pistacia lentiscus* L. leaves essential oil against periodontal bacteria and *Candida* sp. and its anti-inflammatory potential. *Antibiotics* 9: 1-10.
41. Piras A, Marzouki C, Falconieri D, Porcedda S, Gonçalves MJ, Cavaleiro C, Salgueiro L (2017) Chemical composition and biological activity of volatile extracts from leaves and fruits of *Schinus terebinthifolius* Raddi from Tunisia. *Rec Nat Prod* 11:
42. D'Arrigo M, Bisignano C, Irrera P, Smeriglio A, Zagami R, Trombetta D, Romeo O, Mandalari G (2019). *In vitro* evaluation of the activity of essential oil from *Pistacia vera* L. variety Bronte hull against *Candida* sp. *BMC Complement Altern Med*. **2019**, 6. doi: 10.1186/s12906-018-2425-0.
43. Gharibi S, Matkowski A, Sarfaraz D, Mirhendi H, Fakhim H, Szumny A, Rahimmalek M. Identification of polyphenolic compounds responsible for antioxidant, anti-*Candida* activities and nutritional properties in different pistachio (*Pistacia vera* L.) hull cultivars. *Molecules* **2020**, 28: 4772. doi: 10.3390/molecules28124772.
44. Yilmaz G, Ekşi G, Demirci B, Demirci F. Characterization of the fatty acid compositions and antimicrobial activity of sumac (*Rhus coriaria* L.) fruits, growing naturally in Turkey and sold in herbalist markets. *J Fac Pharm Ankara* **2020**, 44: 61-69
45. Vandal J, Abou-Zaid MM, Ferroni G, Leduc L. Antimicrobial activity of natural products from the flora of Northern Ontario, Canada. *Pharm Biol* **2015**, 53: 800-806. doi: 10.3109/13880209.2014.942867.
46. Donati M, Mondin A, Chen Z, Miranda FM, Nascimento Jr BB, Schirato G, Pastore P, Froidi G. Radical scavenging and antimicrobial activities of *Croton zehntneri*, *Pterodon emarginatus*, and *Schinopsis brasiliensis* essential oils and their major constituents: estragole, trans-anethole, β -caryophyllene, and myrcene. *Nat Prod Res* **2015**, 29: 939–946.
47. Gehrke IT, Neto AT, Pedroso M, Mostardeiro CP, Da Cruz IB, Silva UF, Ilha V, Dalcol II, Morel AF (2013). Antimicrobial activity of *Schinus lentiscifolius* (Anacardiaceae). *J Ethnopharmacol* **2013**, 148: 486-491. doi: 10.1016/j.jep.2013.04.043.
48. Turchetti G, Garzoli S, Laghezza Masci V, Sabia C, Iseppi R, Giacomello P, Tiezzi A, Ovidi E. Antimicrobial Testing of *Schinus molle* (L.) Leaf Extracts and Fractions Followed by GC-MS Investigation of Biological Active Fractions. *Molecules* **2020**, 25: 1977. <https://doi.org/10.3390/molecules25081977>
49. El-Nashar HAS, Mostafa NM, El-Badry MA, Eldahshan OA, Singab ANB. Chemical composition, antimicrobial and cytotoxic activities of essential oils from *Schinus polygamus* (Cav.) *cabrera* leaf and bark grown in Egypt. *Nat Prod Res* **2021**, 35: 5369-5372. doi: 10.1080/14786419.2020.1765343.
50. Hernandez C, Taleb-Contini SC, Bartolomeu ACD, Bertoni BC, França SC, Pereira AMS. Chemical composition and antifungal activity of the essential oils of *Schinus weinmannifolius* collected in the spring and winter. *Nat Prod Commun* **2014**, 9: 1383–1386.
51. Freitas MA, Cruz RP, Santos ATL, Almeida-Bezerra JC, Machado AJT, Santos JFS, Rocha JE, Boligon AA, Bezerra CF, Freitas TS. HPLC–DAD analysis and antimicrobial activities of *Spondias mombin* (Anacardiaceae). *Biotechnology* **2022**, 12: 1–15.
52. Costa-Cordeiro BMP, Lima Santos ND, Ferreira MRA, Araújo LCC, Junior ARC. Conceição Santos AD, Oliveira AP, Silva AG, Silva Falcão EP, Santos Correia MT. Silva Almeida JRG, Silva LCN, Soares LAL, Napoleão TC, Silva MV, Paiva PMG. Hexane extract from *Spondias tuberosa* (Anacardiaceae) leaves has

- antioxidant activity and is an anti-*Candida* agent by causing mitochondrial and lysosomal damage. *BMC Complement Altern Med* **2018**, *18*: 1–10.
53. Santos A, Carneiro JNP, Cruz RP, Sales DL, Andrade JC, Almeida CO, Costa JGM, Ribeiro RV, Brito ES, Batista FLA). UPLC-MS-ESI-QTOF analysis and antifungal activity of the *Spondias tuberosa* - arruda leaf and root hydroalcoholic extracts. *Antibiotics* **2019**, *8*: 240.
 54. WFO – World Flora online, <https://www.worldfloraonline.org/> captured in December **2023**.
 55. Hashemi SE, Shokohi T, Abastabar M, Aslani N, Ghadamzadeh M, Haghani I. Species distribution and susceptibility profiles of *Candida* species isolated from vulvovaginal candidiasis, emergence of *C. lusitaniae*. *Curr Med Mycol* **2019**, *5*: 26-36.
 56. Gangneux JP, Dannaoui E, Fekkar A, Luyt CE, Botterel F, De Prost N, Bougnoux, ME. Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French Multicenter MYCOVID study. *Lancet Respirat Med* **2022**, *10*: 180-190.
 57. Costa-de-Oliveira S, Rodrigues AG. *Candida albicans* Antifungal resistance and tolerance in bloodstream infections: the triad yeast-host-antifungal. *Microorganisms* **2020**, *8* (2): 154. doi: 10.3390/microorganisms8020154.
 58. Teodoro GR, Ellepola K, Seneviratne CJ, Koga-Ito CY. Potential use of phenolic acids as anti-*Candida* agents: A Review. *Front Microbiol* **2015**, *6*: 1420.
 59. Ahmed ZB, Yousfi M, Viaene J, Dejaegher B, Demeyer K, Vander Heyden C. Four *Pistacia atlantica* subspecies (*atlantica*, *cabulica*, *kurdica*, and *mutica*): A review of their botany, ethnobotany, phytochemistry, and pharmacology. *J Ethnopharmacol* **2021**, *265*: 113-329.
 60. Iranshahy M, Javadi B, Sahebkar A. Protective effects of functional foods against Parkinson's disease: A narrative review on pharmacology, phytochemistry, and molecular mechanisms. *Phytother Res* **2022**, *36*: 1952– 1989. <https://doi.org/10.1002/ptr.7425>
 61. CLSI - Clinical and Laboratory Standards Institute. Method for broth dilution antifungal susceptibility testing of yeasts: approved M27-A3. *CLSI* **2012**, Wayne, PA, USA.
 62. Abubakar AR, Haque M. Preparation of medicinal plants: Basic extraction and fractionation procedures for experimental purposes. *J Pharm Bioallied Sci* **2020**, *12*: 1-10.
 63. Donadu MG, Peralta-Ruiz C, Usai D, Maggio F, Molina-Hernandez JB, Rizzo D, Bussu F, Rubino S, Zanetti S, Paparella A, Chaves-Lopez C. Colombian essential oil of *Ruta graveolens* against nosocomial antifungal resistant *Candida* strains. *J Fungi* **2021**, *7*: 1-17.
 64. Giordani B, Basnet P, Mishchenko E, Luppi B, Škalko-Basnet N (2019) Utilizing liposomal quercetin and gallic acid in localized treatment of vaginal *Candida* infections. *Pharmaceutics* **2019**, *12*, 9-15.
 65. Rhimi C, Aneke CI, Annoscia G, Otranto D, Boekhout T, Cafarchia C. Effect of chlorogenic and gallic acids combined with azoles on antifungal susceptibility and virulence of multidrug-resistant *Candida spp.* and *Malassezia furfur* isolates. *Med Mycol* **2020**, *58*: 1091–1101.
 66. Maiyoa F, Moodley R, Singh M. Phytochemistry, cytotoxicity and apoptosis studies of β -sitosterol-3-glucoside and β -amyrin from *Prunus africana*. *African J Tradit Complement Altern Med* **2016**, *13*: 105–112.
 67. Kim JE, Kim SS, Hyun C-G, Lee NC. Antioxidative chemical constituents from the stems of *Cleyera japonica* Thunberg. *Int J Pharmacol* **2012**, *8*; 410–415.
 68. El-Alfy TS, Ezzat SM, Hegazy AK, Amer AM, Kamel GM. Isolation of biologically active constituents from *Moringa peregrina* (Forssk.) family: Moringaceae growing in Egypt. *Pharmacogn Mag* **2011**, *7*: 109–115.
 69. Shin S, Pyun M. Anti-*Candida* effects of estragole in combination with ketoconazole or amphotericin B. *Phyther Res* **2004**, *18*: 827–830.
 70. Dąbrowska M, Zielińska-Bliźniewska C, Kwiatkowski P, Łopusiewicz Ł, Pruss A, Kostek M, Kochan E, Sienkiewicz M. Inhibitory effect of eugenol and trans-anethole alone and in combination with antifungal medicines on *Candida albicans* clinical isolates. *Chem Biodivers* **2021**, *18*: 200-223.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.